RxDoctor Payments Data

Muhammad Ali, MD

Cardiovascular Disease · Annandale, VANPI 1699707653

Payments from drug & device makers

$228in general payments, 2019–2025

Across 10 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$100
  • AbbVie$44
  • Sumitomo Pharma America, Inc.$34
  • Pfizer$25
  • Genentech USA, Inc.$13
  • AstraZeneca$12

What the payments were for

  • Food & beverage$12856%
  • Education$10044%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$228 in reported general payments places this provider in the 15th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$175,474
Medicare patients
382
Services billed
2,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$179,489
JanuviaSitagliptin Phosphate49$68,208
JardianceEmpagliflozin38$60,952
JanumetSitagliptin Phos/Metformin Hcl21$34,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$23,792
Tresiba Flextouch U-100Insulin Degludec19$20,480
LinzessLinaclotide19$19,915
MyrbetriqMirabegron21$18,922
FarxigaDapagliflozin Propanediol11$15,826
VascepaIcosapent Ethyl32$9,339
Rosuvastatin Calcium521$9,112
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$8,212
Dexlansoprazole DrDexlansoprazole17$6,737
Breo ElliptaFluticasone/Vilanterol14$5,674
Amlodipine Besylate687$4,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$179,489160 claims
AbbVieLinzess, Synthroid$44$23,14865 claims
Astellas Pharma US IncMyrbetriq$100$18,92221 claims
AstraZenecaFarxiga$12$15,82611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Annandale

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →